Hanmi’s Next-Generation EZH1/2 Dual Inhibitor Demonstrates Potential to Overcome Resistance Mechanisms

HM97662 Exhibits Superior Antitumor Activity Compared to EZH2-Selective Inhibitor Tazemetostat Dr. Young Su Noh (center), Director of Hanmi’s Oncology Clinical Team, presents the latest research findings on HM97662 to attendees, including Dr. Franco Cavalli (fourth from left), and president of the ICML, at the International Conference on Malignant Lymphoma (ICML 2025) held in Lugano, Switzerland. [Press Release] Hanmi Pharmaceutical’s next-generation targeted anticancer therapy, the EZH1/2 dual inhibitor HM97662, has drawn significant attention from global lymphoma experts following precl

Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA

STEQEYMA now matches all dosage forms and strengths of its reference product, STELARA [Press Release] On June 15, Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), in a 45mg/0.5mL solution in a single-dose vial for subcutaneous injection. The additional presentation is approved for the treatment of pediatric patients aged 6 to 17 years, weighing less than 60kg, with plaque psoriasis (PsO) or psoriatic arthritis (PsA).[1] With this approval, STEQEYMA now offe

Daewoong Pharmaceutical and Salipro Biotech, Collaboration Agreement to Advance Development of Novel Therapeutics

[Press Release] On June 11, Swedish biotech company Salipro Biotech AB announced that it has entered into a research collaboration with Daewoong Pharmaceutical. Daewoong Pharmaceutical gains access to Salipro Biotech’s expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong’s development of novel small molecule drugs. Under the terms of this agreement, the co

“Uncertain international circumstances and enlightened self-interest help prevent greater losses.”

[Interview] Joon Oh, Chairman of Save the Children “The ones suffering from the political conflict are the patients… Hope the government and the medical community resolve this through dialogue.” [관련 기사=세이브더칠드런 오준 이사장 “불확실한 국제 정세, 계몽된 자기 이익이 더 큰 손실 막는다”] Save the Children Korea Chairman, Joon Oh [MedigateNews] Amid rising political uncertainty in international affairs and a deepening global economic downturn, Save the Children Korea Chairman, Joon Oh, emphasized the importance of “enlightened self-interest.” He stated, “The term ‘enlightened self

Lunit Study in Radiology Highlights Trust Gap Between Radiologists and AI in Breast Cancer Screening

Despite strong performance from AI, fewer recalls from AI-flagged cases point to challenges in human-AI collaboration [Press Release] SEOUL, South Korea, April 9, 2025-- Lunit(루닛), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the publication of a new study in Radiology (RSNA's flagship journal), highlighting how radiologists interact with AI in real-world breast cancer screening. Lunit’s AI identified more cancers, but radiologists recalled

​U.S. FDA grants interchangeable designation to YUFLYMA, Celltrion's biosimilar to Humira

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar, that is now interchangeable Interchangeable designation of YUFLYMA® is supported by positive data from the Phase III interchangeability study in patients with moderate-to-severe plaque psoriasis [Press Release] INCHEON, South Korea, April 14, 2025 -- Celltrion(셀트리온), Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated YUFLYMA® (adalimumab

K-Beauty Trouble-Care Leader 'Fation' Debuts Nosca9 Deep Pore Cleanser in the U.S

[Press Release] SEOUL, South Korea, April 16, 2025 -- Korean skincare favorite Fation, the top-rated trouble-care brand at Olive Young with a near-perfect 4.9/5.0 rating, has officially launched in the U.S. market. Next rookie following after its best selling 'Trouble' Line, the Nosca9 Deep Pore Cleansing Foam, hit Amazon in March—and the response has been immediate. Named an Amazon "Overall Pick" and boasting an average rating above 4.7 stars, the product is already gaining momentum among beaut

GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine

[Press Release] YONGIN, South Korea, April 9, 2025 -- GC Biopharma(GC녹십자) announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA). With the approval by MFDS, BARYTHRAX has become Korea's 39th novel drug. Following the application on 31 Oct. 2023, GC Biopharma and KDCA successfully received the product approval from MFDS on 8th this mont

Ustekinumab Biosimilars May Ease Budget Pressures and Improve Access in Europe, IMKASID 2025 Analysis Shows

· Total expected savings from ustekinumab biosimilars estimated to be €526 million in Germany, the United Kingdom and Sweden over three years; annual saving per patient estimated to be €5,167, €709, and €3,388 in the respective countries · The Samsung Bioepis and Sandoz* biosimilar Pyzchiva® (ustekinumab) has been commercially available in Europe since July 2024 · Real-world safety and effectiveness of adalimumab biosimilar in Korea based on post-marketing surveillance was also presented at the

A​BL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK

- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules across the blood-brain barrier - ABL Bio to receive up to £77 million in upfront and near-term payments [Press Release] SEONGNAM, South Korea, April 7, 2025 ABL Bio Inc., a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative d